Craig-Hallum Sticks to Its Buy Rating for Grace Therapeutics (GRCE)
Analyst Rating: Chase Knickerbocker from Craig-Hallum maintains a Buy rating on Grace Therapeutics (GRCE) with a price target of $11.00, while the stock currently trades at $3.51.
Market Insights: The overall analyst consensus for Grace Therapeutics indicates a Moderate Buy rating, with an average price target of $11.00, and Knickerbocker has a notable track record in the healthcare sector.
Trade with 70% Backtested Accuracy
Analyst Views on GRCE
About GRCE
About the author
Biotech Stocks Soar in After-Hours Trading: TCMD, BDSX, and EXAS Take the Lead
Tactile Systems Technology Inc. (TCMD): The company saw a 22.13% increase in after-hours trading after reporting a strong Q3 2025 earnings with net income rising to $8.2 million and revenue climbing 17% year-over-year. They also raised their full-year revenue guidance to $317 million - $321 million.
Biodesix Inc. (BDSX): Shares surged 10.57% after the company reported a 20% increase in Q3 2025 revenue to $21.8 million and a narrowed net loss. They raised their full-year revenue forecast to $84 million - $86 million, indicating sustained growth.
Exact Sciences Corp. (EXAS): The stock rose 7.78% following a Q3 2025 earnings report showing a 20% revenue increase to $851 million and a significantly narrowed net loss. The company also raised its full-year revenue guidance to $3.220 - $3.235 billion.
Rani Therapeutics (RANI) and Grace Therapeutics Inc. (GRCE): Rani's shares increased 5.12% ahead of a presentation at ObesityWeek 2025, while Grace's stock rose 6.11% following the full exercise of common warrants tied to a previous funding round, securing additional capital for their drug candidate.
Grace Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for GTx-104
NDA Submission for GTx-104: Grace Therapeutics has submitted a New Drug Application (NDA) to the FDA for GTx-104, an injectable formulation of nimodipine aimed at treating aneurysmal subarachnoid hemorrhage (aSAH), supported by positive results from the Phase 3 STRIVE-ON safety trial.
Financial Implications and Market Potential: The NDA submission could trigger up to $7.6 million in financing warrants, and GTx-104's Orphan Drug Designation may provide seven years of marketing exclusivity, addressing significant unmet medical needs in aSAH treatment.
GRACE THERAPEUTICS Earnings Preview: Recent $GRCE Insider Trading, Hedge Fund Activity, and More
Earnings Release Date: GRACE THERAPEUTICS ($GRCE) is set to announce its quarterly earnings on June 24th, with analysts predicting $0 in revenue and a loss of -$0.32 per share.
Additional Information: The article includes a disclaimer that it is not financial advice and notes potential inaccuracies in the data presented.
Grace Therapeutics Announces Alignment with the FDA Supporting the Planned NDA Submission for GTx-104
FDA Meeting and NDA Submission: Grace Therapeutics announced a productive Type C meeting with the FDA regarding their GTx-104 drug, an injectable formulation of nimodipine for treating aneurysmal subarachnoid hemorrhage (aSAH). The company plans to submit a New Drug Application (NDA) in Q2 2025 based on positive feedback from the FDA.
STRIVE-ON Trial Results: The STRIVE-ON trial demonstrated that GTx-104 significantly reduced clinically significant hypotension compared to oral nimodipine, with better patient outcomes and compliance. The trial's findings support GTx-104 as a promising treatment option for aSAH patients.
Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors
Board Appointments: Matinas BioPharma has appointed Keith Murphy and Edward Neugeboren as independent members of its Board of Directors, effective March 11, 2025, while thanking departing directors Matthew Wikler and Natasha Giordano for their service.
Product Development: The company is advancing its oral antifungal treatment MAT2203, which aims to provide a safer alternative to intravenous amphotericin B, having successfully completed a Phase 2 study in HIV patients with cryptococcal meningitis and planning further evaluation in a Phase 3 trial.
Craig-Hallum Sticks to Its Buy Rating for Grace Therapeutics (GRCE)
Analyst Rating: Chase Knickerbocker from Craig-Hallum maintains a Buy rating on Grace Therapeutics (GRCE) with a price target of $11.00, while the stock currently trades at $3.51.
Market Insights: The overall analyst consensus for Grace Therapeutics indicates a Moderate Buy rating, with an average price target of $11.00, and Knickerbocker has a notable track record in the healthcare sector.
Biotech Stocks Soar in After-Hours Trading: TCMD, BDSX, and EXAS Take the Lead
Tactile Systems Technology Inc. (TCMD): The company saw a 22.13% increase in after-hours trading after reporting a strong Q3 2025 earnings with net income rising to $8.2 million and revenue climbing 17% year-over-year. They also raised their full-year revenue guidance to $317 million - $321 million.
Biodesix Inc. (BDSX): Shares surged 10.57% after the company reported a 20% increase in Q3 2025 revenue to $21.8 million and a narrowed net loss. They raised their full-year revenue forecast to $84 million - $86 million, indicating sustained growth.
Exact Sciences Corp. (EXAS): The stock rose 7.78% following a Q3 2025 earnings report showing a 20% revenue increase to $851 million and a significantly narrowed net loss. The company also raised its full-year revenue guidance to $3.220 - $3.235 billion.
Rani Therapeutics (RANI) and Grace Therapeutics Inc. (GRCE): Rani's shares increased 5.12% ahead of a presentation at ObesityWeek 2025, while Grace's stock rose 6.11% following the full exercise of common warrants tied to a previous funding round, securing additional capital for their drug candidate.
Grace Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for GTx-104
NDA Submission for GTx-104: Grace Therapeutics has submitted a New Drug Application (NDA) to the FDA for GTx-104, an injectable formulation of nimodipine aimed at treating aneurysmal subarachnoid hemorrhage (aSAH), supported by positive results from the Phase 3 STRIVE-ON safety trial.
Financial Implications and Market Potential: The NDA submission could trigger up to $7.6 million in financing warrants, and GTx-104's Orphan Drug Designation may provide seven years of marketing exclusivity, addressing significant unmet medical needs in aSAH treatment.
GRACE THERAPEUTICS Earnings Preview: Recent $GRCE Insider Trading, Hedge Fund Activity, and More
Earnings Release Date: GRACE THERAPEUTICS ($GRCE) is set to announce its quarterly earnings on June 24th, with analysts predicting $0 in revenue and a loss of -$0.32 per share.
Additional Information: The article includes a disclaimer that it is not financial advice and notes potential inaccuracies in the data presented.
Grace Therapeutics Announces Alignment with the FDA Supporting the Planned NDA Submission for GTx-104
FDA Meeting and NDA Submission: Grace Therapeutics announced a productive Type C meeting with the FDA regarding their GTx-104 drug, an injectable formulation of nimodipine for treating aneurysmal subarachnoid hemorrhage (aSAH). The company plans to submit a New Drug Application (NDA) in Q2 2025 based on positive feedback from the FDA.
STRIVE-ON Trial Results: The STRIVE-ON trial demonstrated that GTx-104 significantly reduced clinically significant hypotension compared to oral nimodipine, with better patient outcomes and compliance. The trial's findings support GTx-104 as a promising treatment option for aSAH patients.
Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors
Board Appointments: Matinas BioPharma has appointed Keith Murphy and Edward Neugeboren as independent members of its Board of Directors, effective March 11, 2025, while thanking departing directors Matthew Wikler and Natasha Giordano for their service.
Product Development: The company is advancing its oral antifungal treatment MAT2203, which aims to provide a safer alternative to intravenous amphotericin B, having successfully completed a Phase 2 study in HIV patients with cryptococcal meningitis and planning further evaluation in a Phase 3 trial.
Craig-Hallum Sticks to Its Buy Rating for Grace Therapeutics (GRCE)
Analyst Rating: Chase Knickerbocker from Craig-Hallum maintains a Buy rating on Grace Therapeutics (GRCE) with a price target of $11.00, while the stock currently trades at $3.51.
Market Insights: The overall analyst consensus for Grace Therapeutics indicates a Moderate Buy rating, with an average price target of $11.00, and Knickerbocker has a notable track record in the healthcare sector.
